US Senate targets ‘patent thickets,’ but supporters say it isn't enough
The Senate passed the Affordable Prescriptions for Patients Act by unanimous consent this week, approving a cap on the number of patents asserted in biosimilar litigation. Supporters say the vote reflects...To view the full article, register now.
Already a subscriber? Click here to view full article